A future challenge will be done to validate, through larger prospective studies, whether the administration of albumin preparations or branched-chain amino acid supplements in patients with liver cirrhosis can reduce the incidence of HCC, and whether such interventions can improve prognosis in patients already diagnosed with HCC. This evidence concerns the gene ALB and hepatocellular carcinoma.